How to Get Prolia (Denosumab) in New Mexico

What Is Prolia (Denosumab) and Why Is It Prescribed?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that binds and inhibits RANK ligand (RANKL), the protein responsible for activating osteoclasts. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density (BMD). The FDA approved denosumab for postmenopausal osteoporosis in June 2010 [1], and it has since been approved for bone loss in men receiving androgen-deprivation therapy, women receiving aromatase inhibitors for breast cancer, and glucocorticoid-induced osteoporosis.

The key FREEDOM trial (N=7,868 to 36 months) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68% versus placebo (relative risk 0.32 to 95% CI 0.26 to 0.41, P<0.001) and reduced hip fractures by 40% (P<0.001) [2]. Those numbers explain why the American Association of Clinical Endocrinology (AACE) lists denosumab as a first-line agent for patients at very high fracture risk [3].

Because denosumab is a biologic, it cannot be substituted at the pharmacy counter the way a generic small-molecule drug can. Patients in New Mexico must obtain branded Prolia (or, in specific oncology contexts, Xgeva) from a licensed dispensing source. The 503A compounding pathway described later in this article applies only to an unapproved compounded form of denosumab used in clinical research settings, not to the branded injection for osteoporosis.

Who Can Prescribe Prolia in New Mexico?

Any licensed prescriber with full prescriptive authority in New Mexico may write a Prolia order. That group includes physicians (MD, DO), nurse practitioners (NP), and physician assistants (PA). New Mexico is a full-practice-authority state for NPs under NMSA 1978, Section 61-3-23.2, meaning NPs do not require physician supervision to prescribe Schedule II through V controlled substances or any non-controlled medication including denosumab [4]. PAs in New Mexico must have a supervising or collaborating physician agreement, but that agreement does not require the physician to co-sign each prescription.

Primary care physicians, endocrinologists, rheumatologists, gynecologists, and oncologists all prescribe Prolia in routine practice. The Endocrine Society clinical practice guideline (2019) recommends that the prescribing clinician document a T-score at or below -2.5 or a prior fragility fracture before initiating pharmacotherapy, and that denosumab be considered when bisphosphonates are contraindicated or not tolerated [5].

Telehealth prescribers licensed in New Mexico follow the same standard of care. Under the New Mexico Telehealth Act (NMSA 1978, Section 24-25-1 through 24-25-7), a valid patient-provider relationship can be established via synchronous audio-video encounter, enabling a telehealth clinician to order labs, review a DEXA scan uploaded to a patient portal, and issue a Prolia prescription entirely online [6].

Required Labs and Imaging Before Starting Prolia in New Mexico

Clinicians in New Mexico must confirm that a patient's serum calcium is within normal limits before each Prolia injection. Denosumab lowers osteoclast activity so effectively that it can cause clinically significant hypocalcemia, particularly in patients with vitamin D deficiency. The FDA prescribing information for Prolia states that hypocalcemia must be corrected before initiating therapy and that calcium and vitamin D supplementation should be co-prescribed [1].

The standard pre-treatment workup includes:

• Serum calcium and albumin (to calculate corrected calcium)
• Comprehensive metabolic panel (CMP) including creatinine and eGFR
• 25-hydroxyvitamin D level (target at least 30 ng/mL before first dose)
• DEXA scan of the lumbar spine and hip (establishes baseline T-score)
• Serum phosphorus (flagged by some guidelines for patients with renal impairment)

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends DEXA screening for all women aged 65 and older and for younger postmenopausal women with clinical risk factors, using a T-score threshold of -2.5 or worse to define osteoporosis [7]. A FRAX score calculating 10-year fracture probability can supplement DEXA data, especially when T-scores fall in the osteopenia range (-1.0 to -2.5).

For telehealth patients in New Mexico, DEXA scans can be ordered at outpatient imaging centers across Albuquerque, Santa Fe, Las Cruces, and Roswell, with results transmitted electronically to the prescribing telehealth provider. Lab draws are available at LabCorp and Quest Diagnostics locations throughout New Mexico; results can be uploaded to a patient portal within 24 to 72 hours for telehealth review.

How to Get a Prolia Prescription Through Telehealth in New Mexico

Telehealth is a practical access route for New Mexico residents, particularly those in rural counties such as Mora, Harding, or Catron where endocrinology practices are sparse. The general process runs as follows.

Step 1. Schedule a telehealth consultation. Book a synchronous video visit with a telehealth provider licensed in New Mexico. HealthRX clinicians hold active New Mexico licenses and can see patients from any county in the state.

Step 2. Upload existing records. If you already have a DEXA scan, prior fracture imaging, or lab results from the past 12 months, upload them before the visit. This can shorten time to prescription by eliminating repeat testing.

Step 3. Complete the video encounter. The clinician reviews your fracture history, medication list, renal function, and calcium-vitamin D status. An FRAX risk calculation may be performed during the visit. The Endocrine Society guideline notes that "pharmacologic therapy should be considered in postmenopausal women with a 10-year probability of major osteoporotic fracture of 20% or more or hip fracture of 3% or more using the FRAX algorithm" [5].

Step 4. Receive orders. The clinician sends lab orders electronically and may issue a conditional Prolia prescription held pending lab review.

Step 5. Lab review and final prescription. Once labs confirm normal calcium and adequate vitamin D, the prescription is finalized and sent to a specialty pharmacy or the patient's preferred in-network pharmacy.

Step 6. Administration. Prolia is injected subcutaneously into the abdomen, upper arm, or thigh. In New Mexico, a nurse, pharmacist trained in injection services, or the patient after training can administer it. Many patients return to their provider's office or a local infusion center for each 6-month dose.

Insurance, Prior Authorization, and Cost in New Mexico

Most commercial insurance plans in New Mexico cover Prolia under the pharmacy or medical benefit, but the majority require prior authorization (PA). New Mexico Medicaid (Centennial Care) does not cover Prolia for osteoporosis as of the 2025 fee schedule, though coverage may be available under the medical benefit for oncology indications on a case-by-case basis.

A typical prior authorization for Prolia in New Mexico requires:

• Documentation of a T-score at or below -2.5 on DEXA
• Evidence of an inadequate response to, or contraindication to, an oral bisphosphonate (such as alendronate 70 mg weekly or risedronate 35 mg weekly) for at least 12 months
• Serum creatinine or eGFR (denosumab is preferred over bisphosphonates when eGFR falls below 35 mL/min/1.73 m²) [8]
• ICD-10 diagnosis code (M81.0 for age-related osteoporosis without fragility fracture; M80.00XA for fracture)

The list price for a single Prolia injection is approximately $1,400. Amgen's PROLIA PATIENT ASSISTANCE PROGRAM (PAP) provides free medication to eligible uninsured or underinsured patients with household income at or below 500% of the federal poverty level. Applications are submitted at Amgen Assist 360 (1-888-762-6436) or through a prescribing clinician.

For patients with commercial insurance, Amgen's co-pay card can reduce out-of-pocket costs to as low as $0 per injection for eligible commercially insured patients. Medicare Part D covers Prolia under the pharmacy benefit; Medicare Part B covers it under the medical benefit when administered in a physician's office or clinic [1].

Pharmacy Options for Prolia in New Mexico

Prolia requires cold-chain storage at 36 to 46 degrees Fahrenheit and must not be frozen. That requirement shapes the pharmacy supply chain.

Specialty pharmacies are the most common dispensing route. Major specialty pharmacies operating in New Mexico include CVS Specialty, Walgreens Specialty, and Optum Specialty. These pharmacies ship Prolia directly to a provider's office or to the patient's home in validated cold-chain packaging.

Retail pharmacies with specialty capability exist in Albuquerque (Presbyterian Medical Group pharmacies, University of New Mexico Health pharmacy) and can dispense Prolia when the prescriber sends a direct order.

503A compounding pharmacies licensed in New Mexico may compound patient-specific preparations under NMSA 1978, Chapter 26, Article 1, and they operate under USP Chapter 797 sterile compounding standards [9]. However, compounded denosumab is not bioequivalent to FDA-approved Prolia and is not appropriate for standard osteoporosis treatment. Compounded denosumab preparations appear in clinical research protocols and should not be substituted for brand Prolia without explicit guidance from the prescribing physician.

Transfer of an existing Prolia prescription to a New Mexico pharmacy is straightforward for specialty pharmacies with national networks. The transferring pharmacy sends the prescription and cold-chain shipping instructions; the receiving pharmacy confirms the next scheduled dose date to avoid a gap beyond six months, which can produce a rapid rebound in bone resorption markers [10].

The Risk of Stopping Prolia: A Critical Point for New Mexico Patients

Denosumab is not a drug patients can stop and restart without a plan. The American Society for Bone and Mineral Research (ASBMR) task force report (2017) documented that discontinuing denosumab leads to rapid increases in bone-resorption markers, BMD losses returning to baseline within 12 to 24 months, and an elevated risk of multiple vertebral fractures, sometimes occurring in patients with no prior vertebral fracture history [10]. The FREEDOM Extension data showed that patients who received denosumab for up to 10 years continued to gain BMD, but those who discontinued lost gains quickly [11].

Clinicians in New Mexico initiating denosumab must therefore counsel patients that:

1. Each injection must arrive within six months of the previous dose. Delays beyond six months are associated with rebound vertebral fractures.
2. If denosumab is stopped intentionally, a transition to a bisphosphonate (typically zoledronic acid 5 mg IV once, or alendronate 70 mg weekly for 12 to 24 months) is recommended by both the ASBMR and the Endocrine Society to preserve gained BMD [5].
3. Telehealth providers managing Prolia in New Mexico should program 5-month automated reminders so patients schedule their next dose before the 6-month window closes.

The Journal of Bone and Mineral Research published a 2021 systematic review showing that vertebral fracture rates after denosumab discontinuation were as high as 7.1% within 12 months in patients who did not receive bridging bisphosphonate therapy, compared with 1.5% in those who did receive bridging therapy [12].

Monitoring During Denosumab Therapy in New Mexico

After the first injection, follow-up lab work is lighter than pre-treatment. The minimum monitoring schedule recommended by the FDA prescribing label and corroborated by Endocrine Society guidelines includes:

• Serum calcium at 2 weeks after each injection for the first year (higher risk patients: renal impairment, malabsorption syndromes, hypoparathyroidism)
• 25-hydroxyvitamin D annually
• DEXA scan at 1 to 2 years to assess BMD response, then every 2 years

The FREEDOM trial showed that BMD gains in the lumbar spine averaged 9.2% over 36 months versus -1.4% for placebo [2]. Patients in New Mexico undergoing telehealth-based management can have all monitoring labs drawn locally and results reviewed remotely, with the provider adjusting calcium and vitamin D supplementation as needed.

Patients with a baseline eGFR below 30 mL/min/1.73 m² need closer calcium monitoring because denosumab-induced hypocalcemia is more pronounced in advanced chronic kidney disease. A 2014 cohort study (N=55) published in the Journal of Bone and Mineral Research found that 64% of patients with CKD stage 4 or 5 experienced hypocalcemia within 10 days of denosumab administration [8]. New Mexico's high rates of type 2 diabetes and associated diabetic nephropathy make this a particularly relevant safety consideration for local prescribers.

Osteonecrosis of the Jaw and Atypical Femur Fractures: Rare but Real Risks

Two serious adverse effects require patient education before starting Prolia. Osteonecrosis of the jaw (ONJ) has been reported in patients receiving denosumab, predominantly in oncology patients receiving Xgeva (120 mg monthly) rather than Prolia (60 mg every 6 months). The incidence in osteoporosis patients receiving Prolia is estimated at 0 to 0.2 per 10,000 patient-years of exposure based on post-marketing surveillance data submitted to the FDA [1]. Patients in New Mexico should notify their dentist before starting Prolia and avoid invasive dental procedures during treatment when possible.

Atypical femoral fractures (AFF) are also rare with Prolia. The risk increases with longer duration of use. A 2020 analysis in JAMA Internal Medicine estimated AFF incidence at 11.3 per 100,000 person-years among bisphosphonate and denosumab users combined, compared with 1.0 per 100 to 000 in non-users [13]. Thigh or groin pain during therapy should prompt X-ray evaluation.

The FDA mandates a black-box warning on the Prolia label for both hypocalcemia and ONJ, and clinicians in New Mexico must document the informed-consent discussion in the medical record before the first injection [1].

Bone Health Resources Specific to New Mexico

New Mexico has a relatively older rural population and higher rates of Hispanic descent. Hispanic women in the U.S. have lower DEXA-measured BMD on average compared with non-Hispanic White women at the same age, yet they are less frequently screened, according to CDC NHANES data analyzed in a 2022 JAMA Network Open study (N=6,218) [14]. The BHOF recommends that primary care providers in underserved New Mexico counties prioritize DEXA access through mobile screening units and telehealth-connected reads [7].

University of New Mexico Health Sciences Center in Albuquerque operates an osteoporosis clinic and accepts new patients with or without specialist referral. Presbyterian Healthcare Services, the largest health system in the state, covers DEXA at multiple outpatient imaging sites. For patients without nearby DEXA access, telehealth prescribers can write orders for central DXA at the nearest available site and review results electronically without requiring an in-person follow-up visit.